GU Cancers 2024 | ARTO: local treatment in CRPC undergoing abiraterone treatment

Giulio Francolini, MD, University of Florence, Florence, Italy, discusses findings from a subgroup analysis of the Phase II ARTO trial (NCT03449719) of concomitant stereotactic body radiation therapy (SBRT) with abiraterone and prednisone in patients with oligometastatic castrate resistant prostate cancer (CRPC). The trial has already demonstrated significant benefits in terms of biochemical response and progression-free survival (PFS). The subgroup analysis demonstrated that when oligoprogressive status is detected, SBRT may provide comparable benefits to second-line systemic treatment, suggesting that repeated SBRT is a promising treatment option in selected patients. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.